JW Lifescience Corporation (KRX:234080)
South Korea flag South Korea · Delayed Price · Currency is KRW
11,030
-110 (-0.99%)
Last updated: Aug 3, 2026, 3:00 PM KST

JW Lifescience Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
29,18528,60643,98828,14414,96112,914
Depreciation & Amortization
18,62318,19315,73715,53114,95613,245
Loss (Gain) From Sale of Assets
-83.44-49.7931.79205.8195.87362.94
Asset Writedown & Restructuring Costs
------85
Loss (Gain) From Sale of Investments
---43.5--
Loss (Gain) on Equity Investments
---10,392-6,5324,9214,780
Provision & Write-off of Bad Debts
-35.21-0.44----
Other Operating Activities
-1,409-2,893-1,6381,3991,5752,607
Change in Accounts Receivable
5,146-552.0417,232-2,079-21,1032,576
Change in Inventory
3,5773,129-5,834-1,285-1,057-4,517
Change in Accounts Payable
-3,354-2,624-4,7943,5402,7301,781
Change in Other Net Operating Assets
-4,271-3,272-3,640-1,392-2,950-3,498
Operating Cash Flow
47,37840,53750,69037,57414,12930,165
Operating Cash Flow Growth
-3.85%-20.03%34.91%165.94%-53.16%-35.48%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-12,767-12,554-10,307-8,153-8,079-18,976
Sale of Property, Plant & Equipment
110.56110.564.93.721.71
Cash Acquisitions
---49,437---
Sale (Purchase) of Intangibles
-772.26-878.7661.87-113.8-214.05-259.87
Investment in Securities
110.06-6,51617,036-24,755-655.91
Other Investing Activities
103.05-46.36-14,873-736.19-0.26184.97
Investing Cash Flow
-13,216-13,369-68,0348,037-28,247-22,805

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-197,30020,00043,500139,700157,800
Long-Term Debt Issued
--30,000-44,185770
Total Debt Issued
210,300197,30050,00043,500183,885158,570
Short-Term Debt Repaid
--207,200-10,000-49,500-162,350-145,450
Long-Term Debt Repaid
--8,658-30,481-15,566-677.41-3,483
Total Debt Repaid
-235,251-215,858-40,481-65,066-163,027-148,933
Net Debt Issued (Repaid)
-24,951-18,5589,519-21,56620,8579,637
Repurchase of Common Stock
------6,749
Dividends Paid
-7,742-7,742-7,742-7,742-7,742-7,917
Other Financing Activities
---0--0-
Financing Cash Flow
-32,694-26,3011,776-29,30813,115-5,029

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Miscellaneous Cash Flow Adjustments
--02,857---0
Net Cash Flow
1,468867.39-12,71116,302-1,0032,331

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
34,61127,98340,38329,4216,04911,189
Free Cash Flow Growth
-7.53%-30.71%37.26%386.35%-45.93%-63.70%
Free Cash Flow Margin
13.69%10.85%18.15%14.22%3.20%6.59%
Free Cash Flow Per Share
2235.761807.142608.201900.03390.67718.13
Levered Free Cash Flow
22,96733,1845,91526,7848,71710,273
Unlevered Free Cash Flow
24,74034,9587,20328,46710,64911,073

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,4982,7372,1012,8692,9491,253
Cash Income Tax Paid
6,6329,6465,1136,4336,0449,537
Change in Working Capital
1,097-3,3192,964-1,217-22,381-3,658